DarwinHealth Publishes Results of Novel, Viral Checkpoint-based Technology for Predicting Drugs that Inhibit SARS-CoV-2 Replication: Global Collaboration Highlights Generalizability of Reported ViroTreat Model for Host Cell-Directed Antiviral Drug Discovery,...
NEW YORK, July 19, 2022 /PRNewswire/ -- DarwinHealth, Inc., a New York-based biotechnology and cancer drug discovery company announces the July 19, 2022 online publication in Communications Biology (a Nature Portfolio peer-reviewed journal) of a foundational paper focused on new approaches to antiviral drug discovery, "A model for network-based identification and pharmacological targeting...
In commemoration of World Pharmacists Day 2022, P&G Health lauds pharmacists and the role they play in providing whole-of-body healthcare to patients
P&G Health commemorated World Pharmacists Day 2022 across the Asia Pacific, Middle East, and Africa region through a host of activities This includes the first ever P&G Health Middle-East Whole-Body Health Symposium over 2 days in which 12,813 participants from 111 countries took part SINGAPORE, Sept. 26, 2022 /PRNewswire/ -- P&G Health (NYSE:PG) commemorated World Pharmacists Day 2022...
Lunit Partners with SITC to Launch Exclusive Research Program Featuring Advanced AI Technology for SITC Members
Lunit SCOPE® IO now available to SITC members for AI-powered TME profiling, in a collaborative effort to advance cancer immunotherapy SEOUL, South Korea, Feb. 3, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, has entered into a partnership with the Society for Immunotherapy of Cancer...
Innovent Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress
SAN FRANCISCO and SUZHOU, China, Sept. 18, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that clinical data of IBI363 (first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein) combined with bevacizumab in advanced colorectal cancer is...
RESTORE: The Foundation for Reconstructive Surgery 15th Anniversary Fundraiser Dinner Gala
Celebrating 15 years of FREE Reconstructive Surgeries Around the Globe The most beautiful and kind faces in Hollywood and dignitaries from around the world will come out to celebrate a good cause; the 15th Anniversary RESTORE Fundraiser Dinner Gala is presented by Avi Sivan Abraham Foundation (ASAF), a philanthropic organization based in Cameroon. This magnificent event is hosted...
Navigating the Future of Neurosurgery: Brain Navi demonstrates NaoTrac and KrystoLens at CNS 2023 & EANS 2023
HSINCHU, Aug. 28, 2023 /PRNewswire/ -- Brain Navi announced today the demonstration of NaoTrac, a neurosurgical navigation robot and KrystoLens, a single-use neuro-endoscope at CNS 2023 in Washington D.C. and EANS 2023 in Barcelona, respectively. Brain Navi showcasing its robotic navigation system NaoTrac in Washington DC, and...
Ractigen Therapeutics Announces FDA Orphan Drug Designation for RAG-21 for the Treatment of ALS
NANTONG and SUZHOU, China, Nov. 19, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to RAG-21, its novel siRNA therapy targeting the FUS gene, for the treatment of amyotrophic lateral sclerosis (ALS). RAG-21 is an siRNA therapy...
IND Application for a Phase I/II Clinical Study of Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 was Approved
SUZHOU, China, Dec. 26, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that a phase I/II clinical trial (Study ID: JSKN033-102) of JSKN033, a high-concentration subcutaneous co-formulation consisting of anti-HER2 bispecific antibody-drug conjugate (ADC) and PD-L1 immune checkpoint inhibitor, has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This study...
WuXi Biologics Ranks Top in 2024 Dow Jones Sustainability Indices for Second Consecutive Year
Named for second consecutive year named to prestigious DJSI list Leading green biologics solutions for a healthier future SHANGHAI, Jan. 2, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been named to the 2024 Dow Jones Sustainability Indices (DJSI), and given among...
FDA Approves Direct Biologics to Proceed with a Landmark Phase 3 Acute Respiratory Distress Syndrome (ARDS) Trial
AUSTIN, Texas, April 27, 2022 /PRNewswire/ -- Direct Biologics, a regenerative biotechnology company with a groundbreaking extracellular vesicle (EV) platform technology, announced today that the FDA has approved the company to proceed with its Phase 3 clinical trial using its investigational EV drug, ExoFlo, to treat Acute Respiratory Distress Syndrome (ARDS) due to Covid-19. Direct Biologics is the first...
